A Michigan man has filed a Xarelto gastrointestinal bleed lawsuit claiming that Janssen Pharmaceuticals is to blame for serious injuries he suffered while taking Xarelto.

Plaintiff Gregory D. began taking the popular blood thinning medication, Xarelto, on October 31, 2015 because he suffered from atrial fibrillation.

Because he began using Xarelto, Gregory claims, he experienced severe bleeding injuries including a Xarelto gastrointestinal bleed and rectal bleeding several months later in June 2016.

As a result, Gregory was admitted to the hospital in Livonia, Mich.

He claims that in addition to the Xarelto gastrointestinal bleed and the rectal bleeding, he also suffered serious physical pain and mental anguish, diminished enjoyment of life and financial expenses for hospitalization and medical care.

Xarelto is a newer generation blood thinner that was approved by the Food and Drug Administration (FDA) in 2011 to treat deep vein thrombosis and pulmonary embolism primarily in patients who have undergone lower extremity surgery.

Later that year, Xarelto was also approved to treat stroke risk and/or systemic embolism.

But by early the next year, there were well over one thousand serious adverse bleeding event reports reported to the FDA, including 65 deaths. By the end of 2012, those numbers had risen to 2,000 adverse event reports and 151 deaths.

According to this Xarelto gastrointestinal bleed lawsuit, Janssen allegedly did not conduct proper testing of their drug previous to filing a new drug application as well as ignored clinical evidence and life-threatening bleeding findings.

Gregory claims that even though there was a high risk of a Xarelto gastrointestinal bleed or other types of bleeding, Janssen made, distributed, marketed and sold the drug and did not adequately warn the public or the medical community about the risks.

These Xarelto risks that Janssen allegedly failed to disclose, Gregory claims, include the need for blood monitoring, dose adjustments and serious bleeding that may be irreversible or permanently disabling.

This Xarelto gastrointestinal bleed lawsuit alleges that the failure of Janssen to warn the public about these health risks constitutes flagrant, willful and depraved indifference to health, safety and welfare.

Gregory brings forth the claims of strict liability, manufacturing defect, design defect, failure to warn, negligence, breach of express warranty, breach of implied warranty, negligent misrepresentation and fraud.

This Xarelto Gastrointestinal Bleed Lawsuit is Case No. 2:17-cv-04585-EEF-MBN in the United States District Court of the Eastern District of Louisiana. This is also a part of MDL No. 2592, In re: Xarelto (Rivaroxaban) Products Liability Litigation.

If you believe that you or someone you live have suffered from a Xarelto gastrointestinal bleed, you may benefit from speaking to a Xarelto attorney. You may be entitled to legal compensation.